Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Forthright who wrote (699)	5/13/1998 11:37:00 AM
From: Ms. Forthright	Respond to of 1185

The more I look into this company the more I like it. Nortran has wisely chosen to pursue areas where current treatments are suboptimal or nonexistent. An example of this is the nociblocker. Today, patients with severe pain from cancer, trauma, or other cause are treated with narcotic analgesics. Pain control is very big business. Major pharmaceutical companies have been attempting to improve upon morphine or other "older" molecules. There has been some success with the development of Stadol nasal spray, Fentenyl dermal patches, MS contin slow release morphine, and others. These are expensive and widely prescribed. All share similar problems. Tolerance rapidly develops causing an escalation of dose. This is associated with increasing side effects of sedation, nausea and vomiting, impairment of mental functions, hallucinations, respiratory depression and so on. Imagine a medication that could abolish pain without significant side effects. Think of the value in human terms (and in shareholder terms if you like). Nortran has such a drug in the pipeline.